Long QT syndrome (LQTS) is a primary electrical disorder of the heart characterized by delayed myocardial repolarization, which manifests electrocardiographically as a prolongation of the heart rate-corrected QT interval (QTc) and clinically by an elevated risk of malignant ventricular tachyarrhythmias, particularly Torsades de Pointes (TdP), syncope, and sudden cardiac death (SCD)1,2,4. The estimated prevalence of congenital LQTS is approximately 1 in 2,000 live births, demonstrating a slight female predominance post-puberty1,2. Pathophysiologically, the condition arises from dysfunctional ion channels or regulatory subunits that govern cardiac action potential repolarization, resulting in prolonged cellular refractoriness and increased electrical instability6. While congenital forms follow Mendelian inheritance patterns with broad genetic heterogeneity, acquired forms are frequently precipitated by electrolyte disturbances or exposure to specific xenobiotics and pharmacological agents that block cardiac potassium channels1.
Etiology & Risk Factors
- Congenital (Inherited) LQTS: Caused by monogenic mutations affecting genes encoding cardiac ion channels or membrane-associated regulatory proteins. Over 17 distinct genetic subtypes have been identified, with the three most prevalent accounting for the vast majority of genotyped cases4:
- LQT1: Caused by loss-of-function mutations in the KCNQ1 gene, which encodes the $\alpha$-subunit of the slow delayed rectifier potassium channel ($I_{Ks}$)2.
- LQT2: Caused by mutations in the KCNH2 (formerly HERG) gene, disrupting the rapid delayed rectifier potassium channel ($I_{Kr}$)2.
- LQT3: Caused by gain-of-function mutations in the SCN5A gene, encoding the cardiac sodium channel ($Na_v1.5$), leading to persistent inward sodium current during the plateau phase of the action potential7.
- Inheritance Patterns: Romano-Ward syndrome is the autosomal dominant form manifesting without hearing loss, whereas Jervell and Lange-Nielsen syndrome is an autosomal recessive condition characterized by severe congenital bilateral sensorineural hearing loss coupled with a markedly prolonged QTc interval and high arrhythmic lethality1,4.
- Acquired LQTS: Precipitated by extrinsic factors that impair repolarization reserve, including electrolyte derangements (hypokalemia, hypomagnesemia, hypocalcemia) and administration of QT-prolonging medications (e.g., class IA and III antiarrhythmics, certain macrolide antibiotics, fluoroquinolones, antipsychotics, and antiemetics)1.
- Non-Genetic Clinical Modifiers: Female sex, advanced age, structural bradycardia, underlying left ventricular hypertrophy, and acute neurological insults (e.g., intracranial hemorrhage) significantly amplify repolarization delay and arrhythmic risk1,6.
Pathophysiology
The cardiac action potential depends on a tightly regulated balance between inward depolarizing currents (primarily sodium and calcium) and outward repolarizing potassium currents. In long QT syndrome, genetic mutations disrupt this delicate ionic equilibrium. In LQT1 and LQT2, a reduction in outward potassium currents ($I_{Ks} and I_{Kr}$, respectively) delays membrane repolarization, prolonging the plateau phase (Phase 2) and terminal repolarization (Phase 3) of the ventricular action potential2,6. In contrast, LQT3 stems from gain-of-function mutations in SCN5A that cause pathological, non-inactivating late sodium current influx, maintaining depolarizing inward current throughout Phase 27.
This prolongation of action potential duration across the myocardial wall exhibits significant regional heterogeneity, amplifying transmural dispersion of repolarization. Prolonged cellular refractoriness creates a vulnerable window during which reactivation of L-type calcium channels triggers secondary depolarizations known as early afterdepolarizations (EADs). When EADs reach the threshold voltage, they provoke premature ventricular beats that can initiate self-sustaining runs of polymorphic ventricular tachycardia, classically recognized as Torsades de Pointes. TdP is characterized by cyclical twisting of the QRS complexes around the baseline isoelectric line on the surface ECG. If uncorrected, TdP frequently degenerates into ventricular fibrillation, causing hemodynamic collapse and sudden cardiac death4,6.
Clinical Presentation & Classic Clinical Signs
- History & Cardinal Symptoms: Many individuals with congenital LQTS remain entirely asymptomatic throughout life, with the condition discovered incidentally via family screening or baseline ECGs4. Symptomatic patients typically present with recurrent exertional or stress-induced syncope, presyncope, dizziness, or aborted cardiac arrest. Seizure-like activity is frequently reported during syncopal episodes due to cerebral hypoperfusion, leading to frequent misdiagnoses of primary epilepsy1,4.
- Trigger-Specific Patterns: Clinical presentation is frequently linked to specific genetic triggers. LQT1 events are classically precipitated by physical exertion, emotional stress, or swimming (where sympathetic surge meets an impaired $I_{Ks}$ reserve). LQT2 events are classically provoked by sudden, abrupt auditory stimuli such as alarm clocks, telephone rings, or doorbells. LQT3 events typically occur at rest or during sleep, often manifesting during bradycardic states1,4.
- Physical Examination & Named Clinical Signs: General physical examination is typically unremarkable in isolated Romano-Ward syndrome. In contrast, evaluation of infants with suspected Jervell and Lange-Nielsen syndrome mandates thorough audiological testing to identify profound congenital sensorineural deafness. Cardiovascular examination may reveal a normal resting heart rate and blood pressure, though sudden physical stressors may precipitate abrupt hemodynamic instability or signs of acute heart failure post-resuscitation1,4.
Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)
| Diagnostic Modality / Test | Expected Clinical & Radiological / Laboratory Finding |
|---|---|
| Gold-Standard Investigation | Standard 12-lead electrocardiogram demonstrating a prolonged heart rate-corrected QT interval (QTc > 450 ms in adult males or > 460–470 ms in adult females), evaluated using Bazett's or Fridericia's formula in lead II or V51,2. |
| Laboratory Panel | Serum electrolyte profile demonstrating normal or depleted potassium ($< 4.0\text{ mmol/L}$), magnesium ($< 0.8\text{ mmol/L}$), and calcium levels; comprehensive metabolic panel and thyroid-stimulating hormone (TSH) to exclude secondary metabolic or endocrine contributors to QT prolongation1. |
| Imaging / Radiology (X-ray, US, CT, MRI) | Transthoracic echocardiography showing normal structural anatomy, normal wall thickness, and preserved left ventricular ejection fraction, which helps exclude structural cardiomyopathies and secondary causes of heart failure4. |
| ECG / Histopathology / Procedural | Identification of genotype-specific T-wave morphology: broad-based T waves in LQT1; low-amplitude, notched, or bifid T waves in LQT2; and long, isoelectric ST segments followed by narrow, late-onset peaked T waves in LQT3. Ambulatory Holter monitoring or exercise stress testing may reveal dynamic repolarization changes and rate-dependent QT normalization abnormalities1,2. |
Staging, Classification & Clinical Scoring Systems
| Criterion / Stage / Score Component | Clinical Threshold, Points & Management Implication |
|---|---|
| Schwartz Score: ECG Findings | QTc $\ge 480\text{ ms}$ (3 points); QTc $460\text{-}470\text{ ms}$ (2 points); QTc $450\text{ ms}$ in males (1 point); Torsades de pointes (2 points); T-wave alternans (1 point); Notched T waves in 3 leads (1 point); Low heart rate for age (0.5 points)1,4. |
| Schwartz Score: Clinical History | Syncope with stress (2 points); Syncope without stress (1 point); Congenital sensorineural deafness (0.5 points)1,4. |
| Schwartz Score: Family History | Family members with definitive LQTS (1 point); Sudden unexplained death in immediate family member aged < 30 years (0.5 points)1,4. |
| Risk Stratification & Scoring Interpretation | Total score $\le 1$: low probability of LQTS. Score 1.5–3.0: intermediate probability. Score $\ge 3.5$: high probability of LQTS, warranting definitive genetic screening and initiation of prophylactic therapy1,4. |
Differential Diagnosis
| Differential Condition | Distinguishing Clinical, Biochemical & Imaging Features |
|---|---|
| Brugada Syndrome | Characterized by coved ST-segment elevation in right precordial leads ($V_1\text{-}V_3$) and high risk of ventricular fibrillation, driven by loss-of-function SCN5A mutations rather than prolonged repolarization7. |
| Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | Presents with exercise- or stress-induced bidirectional or polymorphic ventricular tachycardia in the setting of a structurally normal heart and a normal resting QTc interval; caused by mutations in genes regulating intracellular calcium handling (e.g., RYR2)1. |
| Short QT Syndrome | Defined by a markedly shortened QTc interval ($\le 360\text{ ms}$), tall peaked T waves, and high susceptibility to both atrial and ventricular fibrillation caused by gain-of-function potassium channel mutations1. |
| Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) | Progressive fibrofatty replacement of the right ventricular myocardium, presenting with localized structural abnormalities, epsilon waves on ECG, and ventricular arrhythmias displaying a left bundle branch block morphology1. |
Management & Treatment Protocol
- Initial Stabilization & Resuscitation: Immediate management of acute Torsades de Pointes storm requires prompt electrical cardioversion or defibrillation if hemodynamic instability is present. Intravenous administration of magnesium sulfate ($2\text{ g}$ infused over 3–5 minutes) is the first-line pharmacologic maneuver to suppress EADs, even in patients with normal serum magnesium levels. Temporary transvenous pacing or administration of chronotropic agents (e.g., isoproterenol infusion) is utilized to shorten the QT interval by increasing heart rate and suppressing arrhythmogenic pauses1,6.
- First-Line Medical / Pharmacological Therapy (with exact adult dosing): Non-selective beta-blockers represent the cornerstone of chronic management to blunt sympathetic surges that trigger arrhythmias. Nadolol is the preferred agent due to its long half-life and potent $I_{Ks}$ suppression, administered at an initial adult dose of $40\text{ mg}$ orally once daily, titrated upward to $80\text{–}160\text{ mg}$ daily based on clinical efficacy and heart rate response. Propranolol (administered at $20\text{–}40\text{ mg}$ orally three times daily) serves as an alternative non-selective agent. Dihydropyridine calcium channel blockers or selective $\beta_1$-blockers (e.g., metoprolol) are considered less effective and are generally avoided1,2,6.
- Surgical / Interventional Indications: Implantable cardioverter-defibrillator (ICD) therapy combined with beta-blockers is indicated for secondary prevention in survivors of cardiac arrest, or for primary prevention in high-risk patients (e.g., symptomatic individuals despite medical therapy, or those with very high-risk genetic profiles such as LQT2/LQT3 females with markedly prolonged QTc intervals). Left cardiac sympathetic denervation (LCSD) is performed in patients experiencing recurrent breakthrough arrhythmias or ICD shocks despite maximally tolerated beta-blocker therapy1,2.
Complications & Prognosis
- Acute and Chronic Complications: Uncontrolled long QT syndrome carries a significant risk of recurrent syncope, severe anoxic brain injury following aborted cardiac arrest, progression to ventricular fibrillation, and sudden cardiac death. Additional complications include psychological morbidity, anxiety regarding sudden triggers, and device-related complications in patients requiring implantable cardioverter-defibrillators1,4.
- Prognostic Factors: Prognosis is heavily dictated by genetic subtype, baseline QTc duration (with a QTc exceeding $500\text{ ms}$ conferring substantially elevated risk), biological sex, age at diagnosis, and patient adherence to therapeutic regimens. With strict lifestyle modifications, avoidance of QT-prolonging agents, and optimized non-selective beta-blocker therapy, the vast majority of patients with congenital LQTS achieve a near-normal life expectancy and low annual arrhythmic mortality1,2,3.